9 January 2021 - The pERC has conditionally recommended the reimbursement of nivolumab when used in combination with ipilimumab and two cycles of platinum doublet chemotherapy for the first-line treatment of adult patients with metastatic or recurrent non–small cell lung cancer with no known epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumour aberrations, if the cost-effectiveness is improved to an acceptable level.

Eligible patients include those with non-squamous or squamous non-small cell lung cancer, any PD-L1 expression level including patients with unknown PD-L1 expression, and good performance status.

Read initial pERC recommendation for nivolumab